Ligand– tag –
-
Engineered Antibody Brainshuttle™ Technology Boosts Brain Drug Delivery of RNA-Based ASOs by Dual-Targeting TfR1 and CD98hc Receptors, Illuminating CNS Disease Treatment
EMJ Unknown Overview Antibody-based Brainshuttle™ technology has made significant strides in brain drug delivery for promising therapeutics like RNA-based antisense oligonucleotides (ASOs), which are otherwise unable to cross the blood-b... -
EAACI 2026: Wave Life Sciences’ siRNA BW-20805 Shows 93-99% Attack Rate Reduction in Hereditary Angioedema Phase 2, with 60-83% Patients Remaining Attack-Free
EMJ Allergy & Immunology Unknown Overview At the EAACI 2026 conference, updated Phase 2 data for Wave Life Sciences' BW-20805, a plasma prekallikrein-targeting GalNAc-siRNA, revealed highly promising results in adult patients with heredi... -
Identifying Blood-Brain Barrier (BBB) Bottleneck: Nanomedicine Key to Overcoming Glioblastoma Brain Drug Delivery Challenges
Neuroscience News Unknown Overview The blood-brain barrier (BBB), a major obstacle to brain drug delivery, severely limits therapies for neurological disorders like glioblastoma. Recent research identified intracellular sorting after dru... -
Breaking the Blood-Brain Barrier: Next-Gen Strategies Unveil Neurological Drug Delivery Innovation
Pharmaceutical Conferences 2026 International会議 Overview A recent conference on June 22, 2026, showcased groundbreaking drug delivery strategies designed to circumvent the formidable blood-brain barrier (BBB). These innovations, includ... -
UVA’s YuelDesign AI Framework Models Protein Flexibility for Improved Drug Design, Demonstrating Success on CDK2 Target
IntuitionLabs USA Overview The YuelDesign framework, developed by a UVA team, represents a significant advancement in structure-based drug design by explicitly modeling protein flexibility during ligand generation using AI diffusion mode... -
MDPI Highlights AI Drug Discovery’s Clinical Impact Deficit and Validation Crisis: AlphaFold’s Limitations and Regulatory Challenges
MDPI Switzerland Overview A review article by MDPI discusses the current state of AI in drug discovery (2022-2026), noting significant investment and accelerated early-stage discovery timelines but highlighting limited validated clinical... -
AI/Machine Learning Drives Target Identification and Precision Nanomedicine in Drug Discovery, Enhancing Candidate Selection and Pathway Analysis
Dove Medical Press USA Overview Machine learning (ML) and deep learning (DL) strategies are advancing drug discovery by enhancing target identification and precision nanomedicine. These technologies leverage virtual screening and bioacti... -
AlphaFold and AlphaFold 3 Revolutionize Protein Structure and Interaction Prediction, Significantly Accelerating Drug Discovery
IntuitionLabs / dev.to USA Overview AlphaFold and its successor, AlphaFold 3, are dramatically advancing protein structure and molecular interaction prediction, significantly compressing traditional drug discovery timelines. AlphaFold 3 ... -
Next-Gen Perovskite Quantum Dot Solar Cells Achieve Certified 18.3% Efficiency, Advancing Low-Cost, Stable Photovoltaics
RSC Publishing UK Overview Recent advancements in materials science and device engineering have propelled perovskite quantum dot solar cells (QDSCs) to a certified efficiency of 18.3% as of 2025. This breakthrough, driven by low-cost sol... -
Precision RNA Delivery: Preclinical Research Focuses on Targeted LNP Platforms Beyond Hepatic Uptake
jobRxiv USA Overview Preclinical research in LNP-based RNA delivery is prioritizing strategies to overcome inherent liver tropism and achieve targeted delivery to specific cell populations. The goal is to develop and optimize advanced na...
